Kantonsspital St. Gallen | ClinicalTrials HQ

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks	Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder, skin disorder	Active, not recruiting	Phase 3	2025-12-30		NCT02051218
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS	Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, lung disorder, lung neoplasm, malignant colon neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, sarcoma, skin disorder, skin neoplasm	Active, not recruiting	Phase 1 / Phase 2	2025-01-08		NCT05688280